We provide you with 20 years of free, institutional-grade data for APVO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of APVO. Explore the full financial landscape of APVO stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about APVO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Aptevo Therapeutics Inc(NASDAQ:APVO) 
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinic...
Website: http://aptevotherapeutics.com
Founded: 2016
Full Time Employees: 80
Sector: Healthcare
Industry: Biotechnology